Insulet (PODD)
(Delayed Data from NSDQ)
$239.01 USD
+0.04 (0.02%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $239.00 -0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum C VGM
Price, Consensus and EPS Surprise
PODD 239.01 +0.04(0.02%)
Will PODD be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for PODD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PODD
BAX vs. PODD: Which Stock Should Value Investors Buy Now?
Should You Continue to Retain PODD Stock in Your Portfolio Now?
PODD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Insulet's Omnipod 5 Wins FDA Approval for Type 2 Diabetes
Illumina (ILMN) Beats on Q2 Earnings, Lowers 2024 Sales View
Insulet (PODD) Q2 Earnings Miss Estimates, '24 Sales View Raised
Other News for PODD
GE Vernova To Rally Over 30%? Here Are 10 Top Analyst Forecasts For Tuesday
Insulet price target raised by $55 at Piper Sandler, here's why
Piper Sandler Sticks to Its Buy Rating for Insulet (PODD)
Analyst Expectations For Insulet's Future
Insulet Corp (PODD)'s Winning Formula: Financial Metrics and Competitive Strengths